2022年7月11日 · Bleomycin, when applied in a higher concentration topically in the form of a solution or innovative gel/patches, can be tried in treating OL with hopes of better resolution than achieved in our study.

Intralesional bleomycin treatment is effective in hypertrophic scars and warts, but intralesional 5-FU may also be considered since it is cheaper and less painful. Moreover, intralesional 5-FU and bleomycin injection is a viable option for premalignant lesions (i.e., actinic keratosis) and inoperable skin cancers.

2024年8月28日 · Bleomycin was more effective than TAC, 5-FU, or TAC combined with 5-FU for treating keloids and hypertrophic scars with lower skin atrophy and telangiectasia risks. However, it may cause more pain than 5-FU or TAC. Further comprehensive studies, including RCTs, are required for objective analysis.

Intralesional bleomycin has been favorably used off-label to treat various skin conditions. These include warts, hemangiomas, vascular malformations, telangiectasias, several types of cutaneous malignancies, condyloma acuminata, and the lesions of leishmaniasis cutis.

The bleomycin solution should be deposited in the mid-dermal part of keloids to prevent necrosis or ulcerations. In warts, however, bleomycin should be injected in the superficial dermis to induce necrosis. Intralesional bleomycin treatment is well tolerated, but patients experience pain for an average of 2.5 days after the injection.

What is bleomycin? Bleomycin is an antibiotic derived from the fungus Streptomyces verticillus but is mainly used as a chemotherapy drug. It causes DNA strand scission (breakages in the DNA strand), preventing cell replication. Bleomycin is mainly excreted from the body via the kidneys.

Bleomycin is widely used as an off-label treatment for various dermatologic indications. However, a much-needed critical appraisal of the currently available evidence is lacking. We therefore evaluated the quality of clinical evidence for the efficacy and safety of intralesional bleomycin treatment for dermatologic

Bleomycin is widely used as an off-label treatment for various dermatologic indications. However, a much-needed critical appraisal of the currently available evidence is lacking. We therefore evaluated the quality of clinical evidence for the efficacy and safety of …

博莱霉素（Bleomycin, BLM）于1962年发现，于1969年在日本授权为抗肿瘤药物，也在1973年获US FDA许可用于临床药。 BLM是两种主要成分构成的混合物，博莱霉素A2（55-70%）和B2（25-32%）。

The goal is to develop an in situ gel system comprising anionic liposomes (AL) containing bleomycin A6 (BLM A6) dispersed within the thermosensitive in situ gel for sustained release. The results indicated that the gelation temperature decreased due to AL within gel.